On #WorldHealthDay, Abivax celebrates biotech innovations for people with chronic inflammatory diseases. With our lead drug candidate, obefazimod, in Phase 3 trials and a recent US IPO under our belt, we're fueled to advance healthcare, improve lives, and shape a healthier future.
Abivax’s Post
More Relevant Posts
-
#WhatWeDoMatters There is nothing more rewarding than witnessing the sparkle in our kids’ eyes. Curia’s VP, Head of Global R&D Operations, Sripathy Venkatraman, takes pride in explaining to his son, who has a kidney disease, how his work positively impacts the lives of people facing health challenges. —- Learn more about how our end-to-end CDMO services serve independent biotech, big pharma, and everything in between: https://ow.ly/P64R50RheBt
-
-
Did you miss our latest webinar? No problem! We've compiled a comprehensive library of over 20 market access webinar recordings, available on demand for your convenience. 💡 Our goal is to provide valuable resources for your market access journey and keep your team at the forefront of developments in the market access landscape. Here are some of the exciting topics we've recently explored: - Navigating EU HTA: The Future of Supranational HTA Initiatives; Lessons Learned So Far - The Value of Delphi Panels in Accelerating Patient Access - Breaking Down Barriers to Access in Europe: Getting It Right the First Time for Rare Diseases Discover the full range of market access webinars, exclusively available for biopharma companies. Request your recordings here: https://lnkd.in/exewTNnb #webinar #marketaccess #webinarrequest
-
-
Improving outcomes in rare disease requires an industry-wide shift in patient engagement, ensuring that these key stakeholders are involved in every step of drug development and commercialization. Download the whitepaper to learn more from our experts: https://bit.ly/3SRVGDA #AvalereHealth #RareDisease #RareDiseaseMonth
-
#Biosimilars have been on the market for years now. Have they been a boom or a bust for plan sponsors? This week on the blog, Mark Matusik is breaking down realities of pursuing savings with biosimilars space and how plan sponsors can adapt their strategy. As a bonus, tune in as Mark, Megan Dorrell, PharmD, BCACP and Amy Ball break down everything you need to know about this category in our July 10th webinar. Links in the comments! #pharmacybenefitsconsulting
-
-
I welcome anyone interested in learning more on biosimilars to read this quick blog and join this informative session on biosimilars next month!
#Biosimilars have been on the market for years now. Have they been a boom or a bust for plan sponsors? This week on the blog, Mark Matusik is breaking down realities of pursuing savings with biosimilars space and how plan sponsors can adapt their strategy. As a bonus, tune in as Mark, Megan Dorrell, PharmD, BCACP and Amy Ball break down everything you need to know about this category in our July 10th webinar. Links in the comments! #pharmacybenefitsconsulting
-
-
This post highlights a critical yet often overlooked aspect of rare disease trials—the importance of engaging with regulatory frameworks early in the process. T he FDA’s RDEA program serves as a vital resource for biotech companies looking to streamline their trial design and align their endpoints with regulatory expectations. By prioritizing this step, companies can not only safeguard their financial investments but also accelerate the path to bringing innovative treatments to patients in need. In an era where time and resources are more precious than ever, leveraging available regulatory guidance can be the game-changer that distinguishes successful trials from costly setbacks. It's a reminder that proactive planning and consultation can significantly enhance the chances of success in the complex landscape of biotech research. #Biotech #ClinicalTrials #RareDiseases #FDA #RDEA #TrialDesign #DrugDevelopment #RegulatoryAffairs
Most biotech companies miss this crucial step in rare disease trials—do you? Skipping this step can cost millions and years of work, but very few know how easy it is to avoid. The FDA’s RDEA program gives you early access to guidance on validated endpoints, making it easier to avoid costly trial redesigns. Before your next rare disease trial, consult the RDEA program to align your trial design with FDA-approved endpoints. This ensures your trial meets regulatory expectations from the start, cutting down on time and financial risks. Save this post if you're planning a rare disease trial, and make sure you don't miss this crucial step! #Biotech #ClinicalTrials #RareDiseases #FDA #RDEA #TrialDesign #DrugDevelopment #RegulatoryAffairs
-
Most biotech companies miss this crucial step in rare disease trials—do you? Skipping this step can cost millions and years of work, but very few know how easy it is to avoid. The FDA’s RDEA program gives you early access to guidance on validated endpoints, making it easier to avoid costly trial redesigns. Before your next rare disease trial, consult the RDEA program to align your trial design with FDA-approved endpoints. This ensures your trial meets regulatory expectations from the start, cutting down on time and financial risks. Save this post if you're planning a rare disease trial, and make sure you don't miss this crucial step! #Biotech #ClinicalTrials #RareDiseases #FDA #RDEA #TrialDesign #DrugDevelopment #RegulatoryAffairs
-
Check out this post from #risingstar Katarina Zahedi at GlobalData Healthcare! Next month, she will speak on clinical supply strategy at the Clinical Trial Supply East Coast 2024 conference (Clinical Trial Supply Event Series). Can't wait to see what's next!
Last month, I attended Clinical Trials in Rare Disease 2024 in San Francisco, where I spoke on how to optimize and overcome challenges in rare disease trials using data analytics and technology from GlobalData Healthcare. Next month, I will be attending another Arena International Events Group conference, Clinical Trial Supply East Coast 2024 (Clinical Trial Supply Event Series). Looking forward to speaking again alongside other pharma and biotech leaders on clinical supply strategy! Don’t miss my session: Exploring expected trends with clinical supply chain needs from CDMOs. #CTRD #CTSEastCoast #clinicalsupply #supplychaininnovation #datadrivendecisionmaking #bigdataanalytics #optimization
-
-
Our Syneos Health Insights Hub! 👆 Click below to receive the latest biopharma insights directly to your inbox! 📬📩 📰 Subscribe to Syneos Health Weekly Sync https://ow.ly/VNfP30sGXiq #SyneosHealth #WorkHereMatterEverywhere #InsightsHub #BioParma #FutureFocussed #PatientTherapies #WeeklySync #WeeklyNewsletter
Want to receive the latest biopharma insights directly to your inbox? Subscribe to our newsletter, The Syneos Health Weekly Sync, today! https://ow.ly/VNfP30sGXiq #SyneosHealth
-
-
As we recognize Rare Disease Day today, more and more Life Sciences manufacturers shift their focus to underserved rare disease patient populations, how are they going to maximize their impact? With low awareness and a complex journey to treatment, pharma manufacturers face unique barriers to market when launching a rare disease product. Here are 5 winning themes pharma should know to deliver more value to rare disease patients earlier and faster. If you want to support #RareDiseaseDay, check out rarediseaseday.org. #raredisease #lifesciences #innovation
